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Objective: To provide evidence for a rational and effective prevention 
and treatment of Pseudomonas aeruginosa, the clinical characteristics and 
the resistance to various antibiotics of were investigated. Methods: A 
retrospective analysis of 224 strains of Pseudomonas aeruginosa isolated 
from various specimens from various clinical departments of our hospital 
(April 1, 2018 to June 31, 2019) were conducted. Identi cation and drug 
susceptibility test of isolated strains was performed using a fully automatic 
bacterial identi cation analyzer (MicroScan WalkAway-96 plus), and data 
analysis was performed using WH0NET5.6 software. Results: Among all 
the bacteria isolated in our hospital during the above period, Pseudomonas 
aeruginosa accounted for 10.09% of them all and 12.57% of Gram-negative 
bacilli, respectively. These isolates were mainly derived from sputum spec-
imens (68.75%), mainly from male patients (70.54%), and mostly 61-70 
(27.23%) or 51-60 (22.77%) years old. Pseudomonas aeruginosa isolates 
are mainly from Rehabilitation Ward, ICU, and Liver Transplantation Unit, 
accounted for 29.91%, 12.95% and 10.27% of all isolates, respectively. The 
sensitivity of Pseudomonas aeruginosa to various antibacterial drugs, in the 
order of high to low were carbapenems, aztreonam, quinolones, cephalo-
sporins, piperacillin/ tazobactam, aminoglycoside, with a lowest resistance 
rate (2.4%) to amikacin and a highest resistance rate to imipenem (33.0%). 
Conclusion: The isolation rate of Pseudomonas aeruginosa was relatively 
stable during the study period, and among all the P. aeruginosa detected, 
most of them were from the respiratory secretions of elderly male patients. 
The resistance rate of Pseudomonas aeruginosa isolates to various antibiot-
ics is mainly within 30%. Clinical units such as Rehabilitation Ward, ICU, 
and Liver Transplantation Unit have a high detection rate; therefore, these 
departments should be monitored in a focused manner. Our research pro-
vides a scienti c basis for the rational use of antibiotics and a better control 
of Pseudomonas aeruginosa infection.
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1. Introduction
P
seudomonas aeruginosa is a common conditional 
pathogen in clinical practice, widely distributed in the 
natural environment and exists in human skin, respira-
tory tract and intestine. When the body’s natural defenses de-
clines due to surgery, chemotherapy, radiotherapy, hormone 
therapy, etc. they tend to cause pulmonary infections, urinary 
tract infections, otitis media, bacteremia and infections of 
burn wound[1-3]. In recent years, due to the widespread use 
of broad-spectrum antibacterial drugs, the drug resistance of 
the bacteria has increased signi cantly, and caused a severe 
challenge to an effective anti-infective in clinic settings. In 
this study, we analyzed the characteristics, such as drug re-
sistance, of 224 strains of Pseudomonas aeruginosa isolated 
from our hospital from April 1, 2018 to June 31, 2019, and 
expects for a reliable basis for a rational antibiotic policy and 
a better prevention of infection in the future.
2. Materials and Methods
2.1 Strain Specimens and Standard Strains
After removing duplicate strains isolated from the same 
site of the same patient, 224 strains of Pseudomonas 
aeruginosa isolated from various specimens from every 
clinical departments of Lingnan Hospital of the Third Af-
 liated Hospital of Sun Yat-sen University (April 1, 2018 
to June 30, 2019) were included in this analysis. Esch-
erichia coli ATCC25922 and Pseudomonas aeruginosa 
ATCC27853 were used as quality control strains and pro-
vided by the Guangdong Center for Clinical Laboratory.
2.2 Instruments and Reagents
MicroScan Walk-Away 96 plus (Siemens AG, Germany), 
a fully automated bacterial identi cation and susceptibil-
ity analyzer (including supporting reagents and slats) was 
used. Blood agar plate and chocolate agar plate were pro-
vided by Crmicrobio Trading Co., Ltd (Jiangmen, China).
2.3 Strain Identi cation and Drug Sensitivity Test
The culture operations of the specimens sent by the clini-
cal departments are strictly carried out in accordance with 
the National Clinical Laboratory Procedures (4th Edition). 
Identi cation and susceptibility testing of all strains were 
performed using MicroScan Walk-Away 96 plus, deter-
mination of the drug susceptibility test results was carried 
out in accordance with the CLSI 2018 standard.
2.4 Statistical Processing
Data analysis was performed using WH0NET5.6 and 
Excel 2007 software.
3. Results
3.1 Isolation Rate of Pseudomonas Aeruginosa 
Pseudomonas aeruginosa accounted for 10.09% of all the 
bacteria isolated in our hospital from April 1, 2018 to June 
30, 2019, and for Gram-negative bacilli, 12.57% of them 
were Pseudomonas aeruginosa, as shown in Table 1.
Table1. Isolation rate of Pseudomonas aeruginosa
Date
Total 
number of 
strains
number of 
G-b strains
PA
number 
of strains
PA/ Total num-
ber of strains
（%）
PA/
G-b
（%）
April-June 2018 
(summer)
465 378 43 9.25 11.38
July-September 
2018 (autumn)
452 372 48 10.62 12.90
October-December 
2018 (Winter)
388 315 46 11.86 14.60
January to March 
2019 (spring)
410 321 32 7.80 9.97
April-June 2019 
(summer)
506 396 55 10.87 13.89
Total 2221 1782 224 10.09 12.57
3.2 Gender and Age Distribution of Pseudomonas 
Aeruginosa Infections
Of all Pseudomonas aeruginosa strains detected, 158 strains 
(70.54%) were isolated from male patients, and 66 strains 
(29.46%) were isolated from female patients. It was isolat-
ed at all ages, but mainly from 61 -70 (27.23%) and 51-60 
(22.77%) years old patients. In the remaining groups, the 
detection rate of Pseudomonas aeruginosa in patients aged 
71-80 years was 14.73%, and it was 13.39% in the group of 
41-50 years old patients, as shown in Table 2.
Table 2. Gender and age distribution of Pseudomonas 
aeruginosa infections.
age number of patients percentage（%）
<1 2 0.89
1-10 4 1.79
11-20 7 3.13
21-30 14 6.25
31-40 16 7.14
41-50 30 13.39
51-60 51 22.77
61-70 61 27.23
71-80 33 14.73
81-90 6 2.68
Total 224 100.00
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3.3 Distribution of Pseudomonas Aeruginosa In-
fections in Clinical Units
The Pseudomonas aeruginosa cases detected were mainly 
from the Rehabilitation Ward (29.91%), ICU (12.95%), 
Liver Transplantation Unit (10.27%) and Neurosurgery 
department (8.48%). See Table 3.
Table 3. Distribution of Pseudomonas aeruginosa infec-
tions in clinical units
clinical units number of cases percentage（%）
Rehabilitation Ward 67 29.91
ICU 29 12.95
Liver Transplantation 
Unit
23 10.27
Neurosurgery depart-
ment
19 8.48
Respiratory Ward 10 4.46
Department of Infected 
disease
9 4.02
Cardiac surgery unit 8 3.57
Urological ward 8 3.57
Wound care clinic 6 2.68
Rheumatology unit 6 2.68
Others 39 17.41
Total 224 100.00
3.4 The Distribution of Pseudomonas Aeruginosa 
Positive Specimen
The Pseudomonas aeruginosa strains detected were main-
ly isolated from samples such as sputum, urine, wound 
secretions, drainage, organ lavage and blood, as shown in 
Table 4.
Table 4. The distribution of Pseudomonas aeruginosa pos-
itive Specimen
Source of specimen number of cases percentage（%）
sputum 154 68.75
urine 16 7.14
wound secretions 15 6.70
drainage 9 4.02
organ lavage 8 3.57
blood 5 2.23
others 17 7.59
3.5 Susceptibility of Pseudomonas Aeruginosa to 
Various Antimicrobial Agents
The Susceptibility of Pseudomonas aeruginosa strains 
to various antibiotics in this study, ranked from high to 
low, was as follows: imipenem, meropenem, aztreonam, 
levofloxacin, ring Ciprofloxacin, ceftazidime, cefepime, 
piperacillin/tazobactam, gentamicin, tobramycin and ami-
kacin. We observed a lowest resistance rate to amikacin 
(2.4%), while the resistance to imipenem was the high-
est (33.0%). The resistance rate of those Pseudomonas 
aeruginosa strains to carbapenem antibiotics increased in 
2018, but declined in 2019, and it dropped to the lowest 
in the second quarter of 2019 when the resistance rates 
to imipenem and meropenem were 25.5% and 18.2%, re-
spectively. See Table 5.
4. Discussion
Pseudomonas aeruginosa is one of the most common con-
ditional pathogenic bacteria in nosocomial infections[4]. 
Because of its unique characteristics, such as easy coloni-
Table 5. Susceptibility of Pseudomonas aeruginosa strains to antimicrobial agents (%)
In total Summer,2018 Autumn,2018 Winter,2018 Spring,2019 Summer, 2019
antimicrobial agents R S R S R S R S R S R S
Piperacillin/tazobactam 11.5 78.2 9.3 79.1 6.2 91.7 13.0 67.4 12.5 78.1 16.4 74.5
Ceftazidime 13.4 80.4 14.0 83.7 4.2 93.8 17.4 73.9 9.4 78.1 21.8 72.7
Cefepime 11.8 75.4 16.3 76.7 4.2 87.5 10.9 71.7 9.4 71.9 18.2 69.1
Aztreonam 24.9 57.7 34.9 55.8 16.7 62.5 30.4 54.3 18.8 59.4 23.6 56.4
Imipenem 33.0 60.1 30.2 67.4 37.5 54.2 43.5 39.1 28.1 68.8 25.5 70.9
Meropenem 27.6 66.9 23.3 69.8 31.2 60.4 37.0 54.3 28.1 71.9 18.2 78.2
Amikacin 2.4 90.5 0.0 88.4 4.2 89.6 0.0 95.7 6.2 84.4 1.8 94.5
Gentamicin 10.1 75.8 11.6 69.8 4.2 83.3 10.9 80.4 9.4 78.1 14.5 67.3
Tobramycin 5.5 92.1 4.7 90.7 4.2 95.8 6.5 91.3 3.1 93.8 9.1 89.1
Cipro oxacin 18.4 75.3 18.6 72.1 10.4 83.3 15.2 73.9 18.8 78.1 29.1 69.1
Levo oxacin 21.3 69.0 27.9 67.4 16.7 70.8 19.6 69.6 18.8 71.9 23.6 65.5
DOI: https://doi.org/10.30564/jams.v2i4.1212
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zation, variation and multi-drug resistance[5], the infection 
with Pseudomonas aeruginosa often presents a great threat 
to patients, especially those with low immune function 
and those who were admitted to intensive care units[6]. It is 
of great bene t to study the clinical and pathogenic char-
acteristics of Pseudomonas aeruginosa in clinical settings. 
In this study, the detection rate of Pseudomonas aeru-
ginosa was 10.09%, which was consistent with the report 
of Longo et al.[7], in which, Pseudomonas aeruginosa in-
fections accounts for 10%-15% of nosocomial infections. 
68.75% of our isolates were from respiratory specimens. 
The high retention rate of sputum specimen from those af-
fected patients plays a part, but the most possible reason, 
as reported elsewhere[8], is that Pseudomonas aeruginosa 
is the main Gram-negative bacillus causing hospital-ac-
quired pneumonia and ventilator-associated pneumonia, 
most possible due to the reduction of the respiratory 
function by the polysaccharide capsule of Pseudomonas 
aeruginosa. 50% of the isolates were from 51-70 years 
old patients, and 53.13% of the isolates were from Re-
habilitation Ward, ICU, and Liver Transplantation Unit. 
This situation is mainly related to the fact that patients of 
the above-mentioned age group or from the above-men-
tioned wards have more primary disease, generally have 
lower immunity, are subjected to various invasive oper-
ations, prolonged hospital stays and the frequent use of 
broad-spectrum antibacterials, etc.
Pseudomonas aeruginosa has multiple drug resistance 
mechanisms[9-11], mainly, active efflux systems, changes 
of target sites, Bacterial biofilm, inactivated enzyme, 
and foreign resistance genes. According to the results of 
2017 CHINET China bacterial resistance monitoring[12], 
the resistance rate of 16562 strains of Pseudomonas aeru-
ginosa to antimicrobial agents were as follows: aztreo-
nam (31.4%), imipenem (23.6%), ceftazidime (21.4%), 
Meropenem (20.9%), Cefepime (18.7%), Ciprofloxacin 
(14.8%), Piperacillin/tazobactam (13.4%) ,  Gentamicin 
(10.7%) and Amikacin (6.1%). In our study, except for the 
slightly higher resistance rates to imipenem, meropenem, 
and ciprofloxacin, the resistance rates for the remaining 
antibiotics were relatively lower than those of the above 
study. The resistance to aztreonam, quinolones, cepha-
losporins and piperacillin/tazobactam of the strains that 
were in our research were between 11.5% and 24.9%. In 
the past decade, carbapenems have been considered as 
the last line of defense against Gram-negative bacilli. But 
with the increasing use of those drugs, the probability of 
detecting carbapenem-resistant Pseudomonas aeruginosa 
is gradually increasing[13]. In this study, we also noticed 
an increased resistance rate to carbapenem antibiotics in 
2018, however, in 2019, the resistance to imipenem and 
meropenem were controlled and a correspondingly down-
ward trend emerged. In the second quarter of 2019, resis-
tance rates to the two drugs fell to a minimum of 25.5% 
and 18.2%, respectively. This was in line with our hospi-
tals’ close monitoring of microbial resistance as well as 
our clinicians’ effect of strict controlling the use of antibi-
otics, in particular, carbapenem antibiotics. Pseudomonas 
aeruginosa has the lowest resistance rate to aminoglyco-
sides, especially amikacin (2.4%). This may be due to the 
fact that aminoglycosides are nephrotoxic and are rarely 
used in clinic, and also because of the substrate speci city 
of aminoglycoside modifying enzyme mediated resis-
tance.
5. Conclusion
In summary, Pseudomonas aeruginosa is widely distrib-
uted in clinical practice and is one of the most important 
pathogen of nosocomial infections. To effectively prevent 
and control Pseudomonas aeruginosa related nosocomial 
infections, as discussed above, medical staff should pay 
great attention to the rational use of drugs, proper choice 
of antibiotics, the monitoring of pathogens and microbial 
resistance.
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